Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus

M. Isabel Fiel, Kaushik Agarwal, Carmen Stanca, Nassim Elhajj, Nikolas Kontorinis, Swan N. Thung, Thomas D. Schiano – 28 May 2008 – De novo autoimmune hepatitis has been described in both pediatric and adult liver transplantation (LT) recipients. Studies of small numbers of patients have proposed it to be an alloimmune hepatitis or form of chronic rejection. We have recently noted an increasing number of patients with post‐LT recurrent hepatitis C virus (HCV) developing this, with an apparent negative impact on outcome and survival.

Sinusoidal perfusion in the veno‐occlusive region of living liver donors evaluated by indocyanine green and near‐infrared spectroscopy

Takuya Hashimoto, Kenji Miki, Hiroshi Imamura, Keiji Sano, Shoichi Satou, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi – 28 May 2008 – Split liver transplantation and living donor liver transplantation (LDLT) commonly use a right liver graft without the middle hepatic vein (MHV). Although tributaries of the MHV are not reconstructed in the majority of cases, the alterations of the microcirculation and its regional functions remain unknown. We addressed these issues by assessing liver tissue indocyanine green (ICG) uptake with near‐infrared spectroscopy (NIRS) in 21 donors.

Preoperative dobutamine stress echocardiographic findings and subsequent short‐term adverse cardiac events after orthotopic liver transplantation

Lisa G. Umphrey, R. Todd Hurst, Mackram F. Eleid, Kwan S. Lee, Christina S. Reuss, Joseph G. Hentz, Hugo E. Vargas, Christopher P. Appleton – 28 May 2008 – Cardiovascular (CV) complications are the leading cause of non–graft‐related death in orthotopic liver transplant (OLT) patients. Pretransplant cardiac evaluation using dobutamine stress echocardiography (DSE) is commonly utilized for risk stratification of OLT candidates.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

Ming‐Lung Yu, Chia‐Yen Dai, Jee‐Fu Huang, Chang‐Fu Chiu, Yi‐Hsin C. Yang, Nai‐Jen Hou, Li‐Po Lee, Ming‐Yen Hsieh, Zu‐Yau Lin, Shinn‐Cherng Chen, Ming‐Yuh Hsieh, Liang‐Yen Wang, Wen‐Yu Chang, Wan‐Long Chuang – 28 May 2008 – Recommended treatment for hepatitis C virus genotype 1 (HCV‐1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV‐1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks).

Subscribe to